Acute Stroke Intervention

Acute Ischemic Stroke Intervention.

Acute ischemic stroke (AIS) is the leading cause of disability worldwide and among the leading causes of mortality. Although intravenous tissue plasminogen activator (IV-rtPA) was approved nearly 2 decades ago for treatment of AIS, only a minority of patients receive it due to a narrow time window for administration and several contraindications to its use. Endovascular approaches to recanaliza...

Spinal Cord Stroke: Acute Imaging and Intervention

Spinal cord infarction is an uncommon disease and as such is often a diagnostic challenge for clinicians. It can vary in its onset, severity, outcome, and recovery from patient to patient. Treatment options for this relatively rare condition also remain elusive. Current consensus recommendations are antiplatelet therapy and the symptomatic management of associated complications such as parapleg...

Predicting failure of acute stroke intervention.

In 2015, several published clinical trials showed that acute stroke intervention with thrombectomy devices improved outcomes for patients with acute ischemic stroke. An analysis of individual patient data from 5 trials found that the chance for reduced disability at 90 days was substantially higher for patients with large vessel occlusion treated with endovascular therapy (odds ratio 2.49). The...

Regional access to acute ischemic stroke intervention.

BACKGROUND AND PURPOSE Benefit-risk ratios from recombinant tissue plasminogen activator (rtPA) therapy for acute ischemic stroke demonstrate lack of efficacy if intravenous administration is commenced beyond 3 hours of symptom onset. We undertook to enhance therapeutic effectiveness by ensuring equitable access to rtPA for patients affected by acute ischemic stroke within a 20 000 km(2) popula...

Acute stroke intervention results: the "denominator" fallacy.